(IN BRIEF) AstraZeneca announced positive interim Phase III VOLGA trial results showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Immunotherapy Momentum in Bladder Cancer with Positive Phase III VOLGA Trial Readout, AstraZeneca oncology, bladder cancer, Cancer Immunotherapy, cancer recurrence, cancer treatment, cisplatin-ineligible patients, clinical trial results, CTLA-4, durvalumab, enfortumab vedotin, EV, event-free survival, Imfinzi, Imjudo, immunotherapy, MIBC, muscle-invasive bladder cancer, NIAGARA trial, NILE trial, oncology, oncology research, overall survival, PD-L1 inhibitor, Phase III Trial, POTOMAC trial, radical cystectomy, survival outcomes, Susan Galbraith, Thomas Powles, tremelimumab, urothelial carcinoma, VOLGA Phase III Results Position AstraZeneca’s Imfinzi Regimen as Promising New Option for Cisplatin-Ineligible Bladder Cancer Patients, VOLGA trial
(IN BRIEF) Scientists at The Institute of Cancer Research in London have uncovered new details about how the CDK11 enzyme is activated and regulated, providing insights that could support future cancer drug development. Using cryo-electron microscopy, the team mapped the … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amy McGeoch, Breakthrough Research Maps Active CDK11 Complex and Its Role in Gene Expression and RNA Splicing, cancer cell growth, cancer research, Cancer Therapies, CDK11, cell division, cellular biology, cryo-electron microscopy, Cryo-EM, cyclin L, cyclin-dependent kinase, Dr Basil Greber, drug development, enzyme regulation, gene expression, gene transcription, ICR, London, Medical Research Council, Molecular Biology, Nature Communications, New Findings from London Researchers Advance Understanding of Cellular Enzyme Involved in Cancer Growth, oncology research, protein complex, pseudo-substrate, RNA splicing, SAP30BP, Scientists Uncover Structural Secrets of CDK11 That Could Support Future Cancer Drug Development, spliceosome, structural biology, The Institute of Cancer Research, therapeutic research
(IN BRIEF) Researchers at the Institute of Cancer Research have demonstrated how immuno-PET imaging can be used to track the immune system’s response to oncolytic virotherapy in real time. Using a modified virus known as RP1 in preclinical models of … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Immunotherapy, Cancer Research UK, cancer treatment innovation, Chellaram Foundation, Gabriela Kramer Marek, head and neck cancer, ICR London, ICR research demonstrates potential of advanced imaging to guide personalised cancer treatment strategies, immune response, immuno PET, Immuno PET technology offers new insights into timing and effectiveness of cancer immunotherapy combinations, Institute of Cancer Research, Journal of Nuclear Medicine, Julia Höbart, molecular imaging, oncology research, oncolytic virotherapy, Oracle Cancer Trust, PD-L1, RP1 virus
(IN BRIEF) Scientists from the Luxembourg Institute of Health, in collaboration with national clinical and research partners, have developed a functional profiling approach that could significantly enhance personalized treatment strategies for metastatic colorectal cancer. By using patient-derived spheroids—three-dimensional tumour models … Read the full press release
Posted in Business, Healthcare, Industrial, Investment, Luxembourg, Management, Science, Technology
Tagged anti EGFR therapy, cancer drug screening, ERBB2 ERBB3 pathways, functional profiling, Hôpitaux Robert Schuman, Laboratoire National de Santé, Luxembourg Institute of Health, Luxembourg National Research Fund, metastatic colorectal cancer, New Study Demonstrates Predictive Power of Patient-Derived Tumour Models for Personalised Colorectal Cancer Therapy, npj Precision Oncology, oncology research, patient-derived spheroids, personalised medicine, precision oncology, tumour models, Victoria El-Khoury, Yong-Jun Kwon
(IN BRIEF) Researchers from The Institute of Cancer Research and The University of Manchester have created the most comprehensive map of cancer-related genetic mutations to date, analysing data from nearly 11,000 patients in the 100,000 Genomes Project. The study identified … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 100000 Genomes Project, bowel cancer, breast cancer, cancer genomics, David Wedge, DNA mutations, Genomics England, homologous recombination deficiency, HRD, Institute of Cancer Research London, Landmark Study Advances Precision Oncology with Comprehensive Mapping of Cancer-Causing Genetic Mutations, Major Cancer Genomics Study Uncovers New Mutation Signatures Expanding Potential for Precision Treatments, microbiome, mutational signatures, oncology research, ovarian cancer, PARP inhibitors, precision medicine, Richard Houlston, University of Manchester
(IN BRIEF) The Institute of Cancer Research, London, has led the development of OPTIMISE-ROR, the first structured guidance outlining how patient-reported outcomes should be used in early-stage cancer dose-finding trials. Published in the Journal of Clinical Oncology, the recommendations provide … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Research UK, Christina Yap, clinical trials methodology, dose-finding studies, early-stage cancer trials, Emily Alger, Experimental Cancer Medicine Centre, ICR, Institute of Cancer Research Develops First Foundational Framework for Patient-Reported Outcomes in Early Oncology Trials, Institute of Cancer Research London, International Study Led by ICR Strengthens Role of Patient Experience in Early-Phase Cancer Drug Development, Journal of Clinical Oncology, oncology research, OPTIMISE-ROR, patient-reported outcomes, PROs
(IN BRIEF) UK researchers have developed a pioneering blood test using Fourier Transform Infrared microspectroscopy that can detect a single lung cancer cell circulating in the bloodstream. The technique analyses the unique chemical fingerprint of cancer cells, offering a simpler, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Sports, United Kingdom
Tagged blood test, Breakthrough FT IR Technique Could Transform Early Lung Cancer Detection, Cancer Detection, cancer monitoring, circulating tumour cells, early diagnosis, FT IR microspectroscopy, infrared spectroscopy, Josep Sulé Suso, Keele University, liquid biopsy, Loughborough University, lung cancer, NHS cancer care, oncology research, Paul Roach, University Hospitals of North Midlands NHS Trust
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adaptive trial designs, artificial intelligence, biostatistics, cancer trials, clinical research, Clinical Trials and Statistics Unit, Covid-19 pandemic, CTSU, data transparency, Emily Alger, evidence-based decision making, ICR, ICR showcases how statistical science powers cancer research and clinical progress for World Statistics Day 2025, Machine Learning, oncology research, patient-reported outcomes, Professor Christina Yap, quality statistics, responsible research, statistical science, The Institute of Cancer Research celebrates the power of statistics in advancing cancer research ahead of World Statistics Day 2025, The Institute of Cancer Research London, University of Oxford, University of Warwick, World Statistics Day 2025
(IN BRIEF) Roche reported groundbreaking phase III IMvigor011 results showing that Tecentriq (atezolizumab) significantly improved overall and disease-free survival in muscle-invasive bladder cancer using a ctDNA-guided treatment approach. Patients receiving Tecentriq experienced a 41% lower risk of death and a … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged adjuvant therapy, atezolizumab, bladder cancer, Cancer Immunotherapy, ctDNA, disease-free survival, ESMO Congress 2025, IMvigor011, Levi Garraway, molecular residual disease, MRD testing, muscle-invasive bladder cancer, Natera, oncology research, precision oncology, Roche, Roche Advances Personalized Oncology with Positive Phase III Tecentriq Results in ctDNA-Directed Bladder Cancer Treatment, Roche’s Tecentriq Shows 41% Survival Benefit in Landmark ctDNA-Guided Bladder Cancer Study, Signatera, survival benefit, TECENTRIQ, Thomas Powles
(IN BRIEF) Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF 27 million investment. The center is a key part of the company’s strategic efforts to advance next-generation … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged ADC, Basel, Boehringer Ingelheim, Cancer Therapies, CHF 27 million, DGNB Certificate Gold, Jean Engela, Karl Penz, Kaspar Sutter, NBE Therapeutics, oncology research, Swiss biotech, Synaffix B.V., Vienna
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?